Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129675 · ClinicalTrials.gov registry record · Phase 2
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
A Phase 2 study of Parkinsonian Syndrome, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
- 1
- Study location
NCT00129675: Completed Phase 2 study of Parkinsonian Syndrome, sponsored by Institute for Neurodegenerative Disorders.
NCT00129675 is a Phase 2 study of Parkinsonian Syndrome that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 169 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00129675, a Phase 2 study of Parkinsonian Syndrome, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear from a clinical standpoint.
Conditions Studied
Interventions
- DRUG [123I]ß CIT
Study Locations (1)
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00129675 record still lists
NCT00129675 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% higher).
The record links to 1 condition, with Parkinsonian Syndrome appearing as the primary indexed condition, and to 1 intervention - of which [123I]ß CIT is the first listed.
NCT00129675 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00129675 about?
NCT00129675 is a clinical study titled "Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty". The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear from a clinical standpoint.
What is the current status of trial NCT00129675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2003-02. Estimated completion is 2009-05.
What conditions does trial NCT00129675 study?
This clinical trial studies the following conditions: Parkinsonian Syndrome.
What interventions are being tested in trial NCT00129675?
The interventions under investigation include: [123I]ß CIT (DRUG).
Who is sponsoring clinical trial NCT00129675?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00129675 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsonian Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00129675's enrollment target sits among peer trials
169 403rd of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia